BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 26/08/2026

FDA Clears Cabazitaxel Solution for Approval

The FDA has determined that the 60 mg/6 mL (10 mg/mL) concentration of cabazitaxel solution was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.

Source: Federal Register — Health and Human ServicesOpen original release →